Adial Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Adial Pharmaceuticals, Inc. (ADIL) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $51.88 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2024-11-13
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-09-30 was $51.88K, a 4.75% increase year-over-year.
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-06-30 was $48.99K, a 88.54% decline year-over-year.
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-03-31 was $48.99K, a 21.16% decline year-over-year.
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2023-09-30 was $49.53K.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2024-09-30 | $51.88K 10-Q · filed 2024-11-13 | $100.86K derived: sum of 2 quarters · filed 2024-11-13 | $149.85K derived: sum of 3 quarters · filed 2024-11-13 |
| 2024-06-30 | $48.99K 10-Q · filed 2024-11-13 | $97.97K derived: sum of 2 quarters · filed 2024-11-13 | |
| 2024-03-31 | $48.99K 10-Q · filed 2024-11-13 | ||
| 2023-09-30 | $49.53K 10-Q · filed 2024-11-13 | $476.84K derived: sum of 2 quarters · filed 2024-11-13 | $538.98K derived: sum of 3 quarters · filed 2024-11-13 |
| 2023-06-30 | $427.32K 10-Q · filed 2024-11-13 | $489.45K derived: sum of 2 quarters · filed 2024-11-13 | |
| 2023-03-31 | $62.13K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |